289P - The treatment outcome of metastatic prostate cancer patients treated with androgen deprivation therapy in University Malaya Medical Centre

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anti-Cancer Agents & Biologic Therapy
Prostate Cancer
Presenter Prathepamalar Yehgambaram
Citation Annals of Oncology (2016) 27 (suppl_9): ix90-ix93. 10.1093/annonc/mdw584
Authors P. Yehgambaram1, A. Alip2, M. Saad2
  • 1Clinical Oncology, University Malaya Medical Center, 59100 - Kuala Lumpur/MY
  • 2Clinical Oncology, University of Malaya Faculty of Medicine, 50603 - Kuala Lumpur/MY

Abstract

Background

Androgen deprivation therapy (ADT) remains the mainstay of treatment in patients with metastatic prostate cancer. The majority of the patients will become castrate resistant within two years of ADT initiation. We studied the treatment outcome of patients with metastatic prostate cancer treated with ADT at University Malaya Medical Centre (UMMC) and evaluated the prognostic factors affecting the outcomes.

Methods

Metastatic prostate cancer patients who were diagnosed and treated with ADT from January 2004 to January 2014 at UMMC were included in this study. The data was derived from both urology and oncology clinic notes. Treatment outcomes analysed were overall survival and time to prostate specific antigen (PSA) progression. Overall survival (OS) was calculated using Kaplan Meier method. Cox proportional hazards regression model was used to determine the factors influencing the time to PSA progression and overall survival. Log rank test was performed to assess the differences between the groups.

Results

One hundred seventy six patients were included in this study and they had a median follow of 36months. The median time to PSA progression was 17months (95% Confidence interval [CI] 13.3 – 20.7) and median OS after ADT initiation was 50months (95% CI 41.4 -58.6) respectively. The median nadir PSA was 1.44ng/ml and the median time to PSA nadir (TTPN) was 9months. In multivariate analysis, presence of visceral metastasis, initial PSA of 100-500ng/ml and >500ng/ml, nadir PSA>4ng/ml and time to PSA nadir

Conclusions

Visceral metastasis and shorter time to PSA nadir significantly affected time to PSA progression and led to poor survival in metastatic prostate cancer patients treated with androgen deprivation therapy in UMMC.

Clinical trial indentification

Legal entity responsible for the study

University Malaya Medical Centre

Funding

University Malaya Medical Centre

Disclosure

All authors have declared no conflicts of interest.